Form 4: Nuvation Bio Inc. Executive Stacy Markel Reports Stock Option Grant

Stacy Markel, Chief People Officer of Nuvation Bio Inc., reports the acquisition of stock options and shares, including those acquired through the Employee Stock Purchase Plan.

Summary

• Stacy Markel, Chief People Officer of Nuvation Bio Inc., filed a Form 4 on March 4, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of 500,000 stock options with an exercise price of $1.97, vesting over four years from February 28, 2025.
• Markel also reported owning 16,591 shares of Class A Common Stock, including shares acquired through the company's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The document reflects standard insider activity, indicating confidence in the company's prospects, hence a moderately positive sentiment.

Positives

• The grant of stock options to the Chief People Officer aligns her interests with those of the shareholders.
• Participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Future Outlook

The vesting schedule of the stock options incentivizes continued service with the company.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders can monitor insider transactions to gauge management's confidence in the company.
• Employees may be motivated by the fact that the Chief People Officer is participating in the Employee Stock Purchase Plan.

Key Dates